Maintenance of PASI 90 response with guselkumab through 3 years (week 156) among week 28 PASI 90 responders in the VOYAGE 1 study - 22/08/19
K. B. Gordon, Medical College of Wisconsin, Milwaukee, WI; P. Foley, University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, VIC, Australia; C. Leonardi, Central Dermatology, St. Louis, MO; I. Landells, Nexus Clinical Research, St. John’s Newfoundland, Canada; M. Song, Janssen Research & Development, LLC, Spring House; S. Fakharzadeh, Janssen Scientific Affairs, LLC, Horsham, PA; Y-K. Shen, Janssen Research & Development, LLC, Spring House, PA; S. Li, Janssen Research & Development, LLC, Spring House, PA; R. Langley, Dalhousie University, Halifax, Nova Scotia, Canada; K. Reich, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
Le texte complet de cet article est disponible en PDF.| Supported 100% by Janssen Research & Development, LLC. |
Vol 81 - N° 4S1
P. AB90 - octobre 2019 Retour au numéro
Article précédent
- Low-dose methotrexate-induced acute pneumonitis in patient with bullous pemphigoid
- Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?